Magazine Article | March 1, 2021

Inside The Planning Of Audentes' Future Manufacturing Facility

Source: Life Science Leader

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Audentes Therapeutics’ Sanford, NC, facility, which will manufacture the company’s portfolio of adeno-associated virus (AAV)-based gene therapies aimed at targeting serious rare neuromuscular diseases, is slated to be operational this year.

Donald Wuchterl, Audentes’ SVP of technical operations, and Don Mather, executive director, manufacturing & operations site head at Audentes, give some details on the planning stages, equipment needs, challenges, and status of this massive project.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: